Clinical Trial Goal
To find out if the combination of DLI and interferon-Y is safe and works well to treat AML or MDS that has relapsed after allogeneic BMT
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML or MDS that has relapsed after allogeneic BMT
- Do not have engraftment failure. Your doctor can tell you this
- Do not have acute graft-versus-host disease (GVHD) that's grade 3 or 4. Your doctor can tell you this
- Do not have chronic GVHD that doctors consider moderate or severe
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Interferon-Y is a cytokine, or protein, that recruits other parts of your immune system to activate and fight off infection.
You’ll get:
You’ll get:
- DLI – Lymphocytes (a type of white blood cell) from your donor given as an intravenous (IV) infusion up to 2 times
- Interferon-Y - Given as a shot under your skin 1-3 times each week
You may continue treatment for up to 3 months. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using DLI and interferon-Y after allogeneic BMT for relapsed AML or MDS is new and unproven.
Contacts
Linda Elias, RN, 412-623-6037, eliaslj@upmc.edu
Amy Rodger, RN, 412-623-4036, rodgax@upmc.edu
Locations
Washington UniversityRECRUITING
St Louis, Missouri
Contacts:
- Ayan Gasanli, MBA, 314-747-2449, agasanli@wustl.edu
- Ryan Monahan, MBA, 314-454-8377, rmonahan@wustl.edu
UPMC Hillman Cancer CenterRECRUITING
Pittsburgh, Pennsylvania
Contacts:
- Linda Elias, RN, 412-623-6037, eliaslj@upmc.edu
- Amy Rodger, RN, 412-623-4036, rodgax@upmc.edu
Fred Hutchinson Cancer CenterRECRUITING
Seattle, Washington
Contacts:
- Elizabeth Frecker, B.S., SMB-A, 206-667-4129, efrecker@fredhutch.org
- Alisa Bradford, 206-667-2834, ajbradfo@fredhutch.org
Sponsors
collaborator: Evans MDS Discovery Research Grant, collaborator: Amgen, collaborator: FDA Office of Orphan Products Development, lead: Sawa Ito, MD
